Patents by Inventor Mark Andrew Varney

Mark Andrew Varney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of selective serotonin 5-HTreceptor agonists for treating side-effects of VMAT inhibitors
    Patent number: 11191758
    Abstract: The present invention relates to the reduction of the side-effects induced by tetrabenazine or other inhibitors of vesicular monoamine transporter (VMAT), in the treatment of central nervous system disorders such as Huntington's disease, L-DOPA-induced dyskinesias in Parkinson's disease, Tourette's syndrome or tardive dyskinesia. The invention comprises administering to a patient in need thereof an effective amount of activates selective serotonin 5-HT1A receptors agonist, whereby the side-effects of depression or Parkinsonism induced by tetrabenazine or other VMAT inhibitors are minimized.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: December 7, 2021
    Assignees: Neurolixis, Uniwersytet Jagiellonski Collegium Medicum
    Inventors: Anna Wesolowska, Magdalena Jastrzebska-Wiesek, Adrian Newman-Tancredi, Mark Andrew Varney
  • Use Of Selective Serotonin 5-HT1A Receptor Agonists For Treating Side-Effects Of VMAT Inhibitors
    Publication number: 20200155535
    Abstract: The present invention relates to the reduction of the side-effects induced by tetrabenazine or other inhibitors of vesicular monoamine transporter (VMAT), in the treatment of central nervous system disorders such as Huntington's disease, L-DOPA-induced dyskinesias in Parkinson's disease, Tourette's syndrome or tardive dyskinesia.
    Type: Application
    Filed: July 20, 2018
    Publication date: May 21, 2020
    Inventors: Anna WESOLOWSKA, Magdalena JASTRZEBSKA-WIESEK, Adrian NEWMAN-TANCREDI, Mark Andrew VARNEY
  • Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors
    Patent number: 10562853
    Abstract: The invention concerns compounds that possess a high affinity at 5-HT1A receptors and an agonist efficacy, as measured by Emax values from a cellular activation assay, that is higher than that of the compounds described in prior art. The capacity of the compounds of the invention to activate an effector protein complex is higher than that the most efficacious agonist described in prior art. Compounds of the invention also exhibit an exceptionally high selectivity (Ki ratio greater than 1000-fold) with respect, in particular, to dopamine D2 receptors and adrenergic receptors of the alpha1 subtype. This selectivity which constitutes a great advantage since it means that the compounds will avoid inducing (central and peripheral) effects associated with activating or inhibiting such receptors.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: February 18, 2020
    Assignees: NEUROLIXIS, UNIVERSITE JAGELLONE
    Inventors: Joanna Sniecikowska, Adam Bucki, Adrian Newman-Tancredi, Mark Andrew Varney
  • COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS
    Publication number: 20190194132
    Abstract: The invention concerns compounds that possess a high affinity at 5-HT1A receptors and an agonist efficacy, as measured by Emax values from a cellular activation assay, that is higher than that of the compounds described in prior art. The capacity of the compounds of the invention to activate an effector protein complex is higher than that the most efficacious agonist described in prior art. Compounds of the invention also exhibit an exceptionally high selectivity (Ki ratio greater than 1000-fold) with respect, in particular, to dopamine D2 receptors and adrenergic receptors of the alpha1 subtype. This selectivity which constitutes a great advantage since it means that the compounds will avoid inducing (central and peripheral) effects associated with activating or inhibiting such receptors.
    Type: Application
    Filed: June 23, 2017
    Publication date: June 27, 2019
    Applicants: NEUROLIXIS, UNIVERSITE JAGELLONE
    Inventors: Joanna SNIECIKOWSKA, Adam BUCKI, Adrian NEWMAN-TANCREDI, Mark Andrew VARNEY
  • Pyridine derivatives
    Patent number: 6656957
    Abstract: A compound of formula I wherein X represents an optionally halo-substituted (C2-4)alkynylene group bonded via vicinal unsaturated carbon atoms.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: December 2, 2003
    Assignees: Novartis AG, Sibia Neurosciences Inc.
    Inventors: Hans Allgeier, Yves Auberson, Michel Biollaz, Nicholas David Cosford, Fabrizio Gasparini, Roland Heckendorn, Edwin Carl Johnson, Rainer Kuhn, Mark Andrew Varney, Gönül Veliçelebi
  • MGluR5 antagonists for the treatment of pain and anxiety
    Publication number: 20010056084
    Abstract: The invention provides the use of selective mGluR5 antagonists for the treatment of pain and anxiety, and the use of mGluR antagonists for the treatment of pain, whereby analgesic effect is achieved by interaction of said antagonists primarily or predominantly at peripheral mGluR receptors.
    Type: Application
    Filed: March 29, 2001
    Publication date: December 27, 2001
    Inventors: Hans Allgeier, Nicholas David Cosford, Peter Josef Flor, Fabrizio Gasparini, Conrad Gentsch, Stephen D. Hess, Edwin Carl Johnson, Rainer Kuhn, Mark Tricklebank, Laszlo Urban, Mark Andrew Varney, Gonul Velicelebi, Katharine Walker